Overview
New York, NY – Oct 05, 2026 – The Global Enteric Softgel Capsules Market size is expected to be worth around US$ 4.0 Billion by 2034 from US$ 2.8 Billion in 2024, growing at a CAGR of 3.7% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 41.9% share with a revenue of US$ 0.3 Billion.
The global Enteric Softgel Capsules Market is witnessing steady growth, driven by increasing demand for advanced drug-delivery solutions and growing pharmaceutical applications. Enteric softgel capsules are designed to resist dissolution in the stomach and release their contents in the intestine, making them suitable for drugs and supplements that require protection from gastric conditions.
Market growth is being supported by the rising prevalence of gastrointestinal disorders, increasing consumption of dietary supplements, and growing adoption of patient-friendly oral dosage forms. Pharmaceutical manufacturers are also focusing on improved formulation technologies to enhance drug stability, bioavailability, and targeted release.
North America and Europe represent significant markets due to established pharmaceutical industries, while Asia-Pacific is expected to offer considerable growth opportunities owing to expanding healthcare infrastructure, increasing pharmaceutical production, and rising healthcare expenditure.
Key companies operating in the market are focusing on product innovation, manufacturing capacity expansion, strategic partnerships, and research and development activities to strengthen their market positions. Continued technological advancements and increasing demand for controlled and targeted drug delivery are expected to create new opportunities for market participants.
Key Takeaways
- In 2024, the market was valued at US$ 2.8 billion and is projected to grow at a CAGR of 3.7%, reaching approximately US$ 4.0 billion by 2034.
- By product type, the market is segmented into gelatin (Type-A & Type-B), fish bone gelatin, starch material, and cellulose derivatives. Among these, gelatin (Type-A & Type-B) dominated the market in 2024, accounting for a 58.6% share.
- Based on application, the market is categorized into health supplements, anti-inflammatory drugs, vitamin and dietary supplements, antibiotic & antibacterial drugs, and others. The health supplements segment held the largest share, representing 42.4% of the market.
- By end user, the market is segmented into pharmaceutical companies, cosmeceutical companies, nutraceutical companies, and the food industry. Pharmaceutical companies dominated the market in 2024, accounting for 47.8% of the total revenue share.
- Regionally, North America led the global market in 2024, accounting for a significant 41.9% market share.
Key Market Segments
- Product Type Analysis: Gelatin Type A and Type B accounted for 58.6% of the product type segment. Its strong film-forming properties, predictable dissolution, scalability, regulatory familiarity, and cost efficiency support widespread adoption. Gelatin also enables consistent shell thickness, coating adhesion, and reliable encapsulation for pharmaceutical formulations.
- Application Analysis: Health supplements accounted for 42.4% of the application segment, driven by rising demand for effective intestinal delivery and improved ingredient absorption. Enteric softgels are increasingly used for probiotics, enzymes, omega fatty acids, and botanical extracts. Growing digestive health awareness and preventive nutrition trends further support demand.
- End-User Analysis: Pharmaceutical companies represented 47.8% of the end-user segment and remained the leading adopters. Enteric softgels are increasingly used to protect acid-sensitive active ingredients, enable targeted intestinal release, reduce gastric irritation, and improve patient adherence. Established regulatory pathways and scalable manufacturing further strengthen pharmaceutical adoption.
Regional Analysis
North America
North America dominated the Enteric Softgel Capsules Market in 2024, accounting for 41.9% of the global share. Growth was supported by rising demand for targeted-release formulations across nutraceuticals and over-the-counter pharmaceuticals.
Increasing use of enteric softgels for omega-3 supplements, probiotics, vitamins, and anti-inflammatory drugs further strengthened regional adoption. Growing health awareness, aging populations, and demand for reduced gastrointestinal side effects supported market expansion.
Innovations in plant-based coatings also addressed vegan and allergen-free preferences. Established pharmaceutical manufacturing capabilities, advanced research activities, strong distribution networks, and stringent quality standards further reinforced North America’s market leadership.
Asia Pacific
Asia Pacific is projected to register the highest CAGR during the forecast period. Growth is being driven by expanding nutraceutical consumption, increasing pharmaceutical manufacturing, and government initiatives supporting domestic production.
Enteric softgels are increasingly incorporated into vitamins, minerals, herbal formulations, probiotics, and therapeutic drugs. Rising healthcare awareness, improving pharmaceutical infrastructure, and growing demand for advanced drug-delivery systems are expected to accelerate adoption.
China and other emerging economies are anticipated to provide significant growth opportunities due to expanding healthcare investments and pharmaceutical innovation.
Emerging Trends
- Growing use for acid-sensitive drugs: Enteric softgels are increasingly relevant for medicines that can be damaged by stomach acid. The enteric layer helps protect the active ingredient and can support delivery further into the gastrointestinal tract.
- Interest in poorly soluble drug delivery: Softgels can hold liquid or semi-solid formulations, which makes them useful for poorly water-soluble compounds. This capability can support improved drug solubilization and oral bioavailability for selected compounds.
- Development of new delayed-release technologies: Pharmaceutical companies are evaluating alternatives to conventional enteric coatings, including polymer-based capsule technologies. A 2025 FDA workshop highlighted delayed-release softgels using enteric coatings and pectin-based approaches, showing continued innovation in this area.
- Greater focus on dissolution performance: Quality testing is becoming increasingly important because softgel structure, gelatin properties, formulation composition, and coating can affect drug release. Scientific literature identifies dissolution testing as an important challenge in the development of softgel products.
- Stronger regulatory focus on modified-release quality: Regulatory agencies are placing clear emphasis on the quality, dissolution, bioavailability, and pharmacokinetic performance of delayed-release medicines. EMA specifically provides guidance covering oral delayed-release products based on gastro-resistance.
Use Cases
- Protection of acid-sensitive APIs: Enteric softgels can be used when an active pharmaceutical ingredient may degrade or become inactive in the acidic stomach. The delayed-release design allows the medicine to reach the intestine before substantial release occurs.
- Reduction of stomach irritation: Enteric protection can be useful when direct exposure of the stomach to a drug is undesirable. FDA notes that enteric coatings may be indicated when a drug can irritate the gastric mucosa.
- Targeted intestinal drug release: These capsules can be designed to provide delayed release after gastric transit. This makes them suitable for formulations where intestinal delivery is preferred over immediate release in the stomach.
- Delivery of lipid-based formulations: Softgels are well suited to liquid and lipid-based fills. Their use can be considered for compounds where formulation in a lipid or semi-solid system may improve solubilization and oral absorption.
- Modified-release pharmaceutical products: Enteric softgels can form part of broader modified-release strategies. Regulatory frameworks recognize delayed-release capsules as modified-release products and require suitable evaluation of their release and performance characteristics.
Frequently Asked Questions About Enteric Softgel Capsules
- How do enteric softgel capsules work?
An enteric softgel is designed to remain intact during stomach exposure and release its contents later. This delayed release is generally achieved through an enteric coating or specialized capsule technology that provides gastro-resistant performance. - Why are enteric softgels used in pharmaceutical formulations?
Enteric softgels are used when protection from stomach acid, reduced gastric exposure, or intestinal delivery is required. They can also provide a suitable dosage form for liquid and lipid-based formulations containing poorly water-soluble active ingredients. - Are enteric softgels suitable for acid-sensitive drugs?
Yes. Enteric delivery can be particularly useful for acid-sensitive active ingredients because the dosage form is designed to delay exposure of the drug to the acidic stomach environment. However, suitability depends on the specific drug and formulation characteristics. - Can enteric softgels improve drug absorption?
Enteric softgels can support absorption in selected formulations, but improved absorption is not automatic. Performance depends on drug properties, formulation design, gastrointestinal conditions, coating technology, dissolution behavior, and other factors affecting oral bioavailability. - What types of ingredients can be filled into softgels?
Softgels can accommodate liquid, semi-solid, and certain lipid-based formulations. This flexibility makes them useful for compounds requiring solubilization approaches that may be difficult to achieve with conventional solid oral dosage forms. - Which pharmaceutical applications are important for enteric softgels?
Important applications include acid-sensitive drugs, medicines requiring intestinal delivery, products where gastric irritation should be reduced, and lipid-based formulations. The exact application depends on the active ingredient, therapeutic objective, and required release profile. - What is the future outlook for enteric softgel capsules?
The outlook is supported by continued development of advanced oral drug delivery systems, poorly soluble drug formulations, lipid-based technologies, and alternative delayed-release approaches. Innovation is expected to focus on reliable release, manufacturing efficiency, formulation stability, and product quality.
Conclusion
The Enteric Softgel Capsules Market is expected to witness steady growth, supported by increasing demand for advanced oral drug-delivery systems, rising use of health supplements, and growing pharmaceutical applications.
The ability of enteric softgels to protect active ingredients from gastric conditions and provide targeted intestinal release is strengthening their adoption across pharmaceuticals and nutraceuticals. Gelatin-based capsules remain widely preferred due to their favorable manufacturing and formulation properties.
North America currently leads the market, while Asia-Pacific is expected to provide significant growth opportunities. Continued innovation in delayed-release technologies, improved bioavailability, plant-based materials, and manufacturing processes is expected to support long-term market development.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
